ติดต่อลงโฆษณา racingweb@gmail.com

ผู้เขียน หัวข้อ: The Role of ADCC and CDC Assays in Immunotherapeutic Research  (อ่าน 37 ครั้ง)

0 สมาชิก และ 1 บุคคลทั่วไป กำลังดูหัวข้อนี้

ออฟไลน์ pysong

  • Sr. Member
  • ****
  • กระทู้: 260
    • ดูรายละเอียด
The Role of ADCC and CDC Assays in Immunotherapeutic Research
« เมื่อ: 19/12/24, 09:09:12 »
The Role of ADCC and CDC Assays in Immunotherapeutic Research

Abstract: Antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) are critical mechanisms of action for therapeutic antibodies in cancer and infectious disease treatments. This article explores the principles, methodologies, and significance of ADCC and CDC assays in evaluating the efficacy of antibody-based therapies.To get more news about ADCC & CDC Assays, you can visit probiocdmo.com official website.

Introduction: Antibody-based therapies have revolutionized the field of immunotherapy, providing targeted treatments for various malignancies and infections. Among the key mechanisms through which these therapies exert their effects are antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). These assays are essential tools in preclinical and clinical research for understanding and optimizing the therapeutic potential of antibodies.

Mechanisms of ADCC and CDC: ADCC is a mechanism by which immune effector cells, such as natural killer (NK) cells, recognize and kill target cells that are bound by specific antibodies. This process involves the Fc region of the antibody interacting with Fc receptors on the effector cells, triggering the release of cytotoxic granules that lead to target cell lysis.

CDC, on the other hand, involves the activation of the complement system by antibodies bound to the surface of target cells. The complement cascade results in the formation of the membrane attack complex (MAC), which creates pores in the target cell membrane, leading to cell death.

Methodologies:

ADCC Assay: Typically involves co-culturing effector cells with target cells in the presence of specific antibodies. The lysis of target cells is measured using various techniques, such as flow cytometry or cytotoxicity assays, which quantify the release of lactate dehydrogenase (LDH) or other markers of cell death.

CDC Assay: Involves incubating target cells with antibodies and complement proteins. The extent of complement-mediated lysis is assessed using similar cytotoxicity assays that measure the release of intracellular contents or the incorporation of viability dyes.

Significance in Research: ADCC and CDC assays are invaluable in the development and optimization of therapeutic antibodies. They provide insights into the potency and specificity of antibody candidates, guiding modifications to enhance their efficacy. These assays also help predict the clinical performance of antibodies, contributing to the design of better therapeutic strategies.

Applications:

Cancer Therapy: ADCC and CDC assays are used to evaluate the efficacy of monoclonal antibodies targeting tumor-associated antigens.

Infectious Diseases: These assays help in assessing the therapeutic potential of antibodies against viral and bacterial pathogens.

Autoimmune Disorders: Understanding the role of ADCC and CDC in antibody-mediated destruction of autoimmune targets aids in developing treatments with reduced off-target effects.

Conclusion: The ADCC and CDC assays are fundamental to the advancement of antibody-based therapies. By providing a deeper understanding of the mechanisms of action and therapeutic potential of antibodies, these assays play a crucial role in the development of next-generation immunotherapeutics.